英夫利西单克隆抗体治疗炎症性肠病的疗效预测标志物研究进展

Research progress on predictors of response to infliximab in patients with inflammatory bowel disease

英夫利西单克隆抗体(IFX)是最早应用于炎症性肠病(IBD)治疗的生物制剂之一,使用也最为广泛。但在实际应用中,因IFX治疗存在较高比例的原发性或继发性失应答,部分IBD患者的临床获益有限。因此,在治疗前预测生物制剂疗效,从而寻找适宜人群进行IFX治疗是关注的热点问题。本文就近年报道的IFX治疗IBD的疗效预测标志物及其功能进行综述。

Infliximab(IFX)is one of the earliest and most widely used biologics for inflammatory bowel disease(IBD).However,due to the high proportion of primary non-response and secondary loss of response,its clinical benefit is limited among patients.Therefore,it is important for specialists to predict the efficacy of biological agents before treatment.This article reviews the recent reports on predictive markers of IFX response and their functions.